SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330) (KTTA) — Nov 21, 2025

Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330)
Date: Nov. 21, 2025 · CIK: 0001841330 · Accession: 0001213900-25-113646

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-291611

Date
November 21, 2025
Author
Dr. Tiago Reis Marques
Form
CORRESP
Company
Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330)

Letter

Re: Pasithea Therapeutics Corp. (the "Company")

November 21, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (File No. 333-291611) Filed on November 18, 2025

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on November 19, 2025, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for November 20, 2025, at 5:15 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.

Please call James O'Grady of Lowenstein Sandler LLP at (646) 414-6849 with any questions.

Very truly yours,
PASITHEA THERAPEUTICS CORP.

Show Raw Text
CORRESP
 1
 filename1.htm

 November 21, 2025

 VIA EDGAR

 United States Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

 Washington, D.C. 20549

 Re:
 Pasithea Therapeutics Corp. (the "Company")

 Registration Statement on Form S-1 (File No. 333-291611)
 Filed on November 18, 2025

 Ladies and Gentlemen:

 Reference is made to our letter, filed as correspondence
via EDGAR on November 19, 2025, in which we requested the acceleration of the effective date of the above-referenced Registration Statement
for November 20, 2025, at 5:15 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no
longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for
acceleration of the effective date.

 Please call James O'Grady of Lowenstein
Sandler LLP at (646) 414-6849 with any questions.

 Very truly yours,

 PASITHEA THERAPEUTICS CORP.

 By:
 /s/ Dr. Tiago Reis Marques

 Dr. Tiago Reis Marques

 Chief Executive Officer